{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:47:28Z","timestamp":1771616848483,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To assess in a single study the individual and treatment characteristics that influence the pharmacokinetics and pharmacodynamics of natalizumab in multiple sclerosis (MS) patients in the real-world practice.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Prospective observational study to analyse the impact of body weight, height, body surface area, body mass index, gender, age, treatment duration, and dosage scheme on natalizumab concentrations and the occupancy of \u03b14-integrin receptor (RO) by natalizumab.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Natalizumab concentrations ranged from 0.72 to 67 \u03bcg\/ml, and RO from 26 to 100%. Body mass index inversely associated with natalizumab concentration (beta = \u22121.78; <jats:italic>p<\/jats:italic> \u2264 0.001), as it did body weight (beta = \u22120.34; <jats:italic>p<\/jats:italic> = 0.001), but not height, body surface area, age or gender Extended vs. standard dose scheme, but not treatment duration, was inversely associated with natalizumab concentration (beta = \u22127.92; <jats:italic>p<\/jats:italic> = 0.016). Similar to natalizumab concentration, body mass index (beta = \u22121.39; <jats:italic>p<\/jats:italic> = 0.001) and weight (beta = \u22120.31; <jats:italic>p<\/jats:italic> = 0.001) inversely impacted RO. Finally, there was a strong direct linear correlation between serum concentrations and RO until 9 \u03bcg\/ml (rho = 0.71; <jats:italic>p<\/jats:italic> = 0.003). Nevertheless, most patients had higher concentrations of natalizumab resulting in the saturation of the integrin.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Body mass index and dosing interval are the main variables found to influence the pharmacology of natalizumab. Plasma concentration of natalizumab and\/or RO are wide variable among patients and should be routinely measured to personalize treatment and, therefore, avoid either over and underdosing.<\/jats:p>","DOI":"10.3389\/fneur.2021.716548","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T11:45:41Z","timestamp":1633693541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses"],"prefix":"10.3389","volume":"12","author":[{"given":"Jose M.","family":"Serra L\u00f3pez-Matencio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaiza","family":"P\u00e9rez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Ju\u00e1rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles","family":"Ursa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Vega-Piris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Pascual-Salcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Mu\u00f1oz-Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/HAB-1997-8102","article-title":"Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis","volume":"8","author":"L\u00e9ger","year":"1997","journal-title":"Hum Antibodies."},{"key":"B3","unstructured":"Renewing and Amending the Marketing Authorisation for the Medicinal Product for Human Use and Quot; Tysabri - Natalizumab and Quot; granted by Decision C2006"},{"key":"B4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab","volume":"65","author":"Del Pilar Martin","year":"2008","journal-title":"Arch Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jaci.2016.11.045","article-title":"Recognition of viral and self-antigens by TH1 and TH1\/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses","volume":"140","author":"Paroni","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J Clin Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/acn3.190","article-title":"CD4 cell response to interval therapy with natalizumab","volume":"2","author":"Berkovich","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B15","unstructured":"Natalizumab: Summary of Product Characteristics2020"},{"key":"B16","unstructured":"Tocilizumab: Summary of Product Characteristics2020"},{"key":"B17","unstructured":"Rituximab: Summary of Product Characteristics2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald Criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"Du Bois","year":"1916","journal-title":"Arch of Int Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1079\/BJN19910073","article-title":"Body mass index as a measure of body fatness: age- and sex-specific prediction formulas","volume":"65","author":"Deurenberg","year":"1991","journal-title":"Br J Nutr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal Biochem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"Van Kempen","year":"2017","journal-title":"Mult Scler."},{"key":"B30","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis","year":"2019","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS - a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.716548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T11:45:46Z","timestamp":1633693546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.716548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":34,"alternative-id":["10.3389\/fneur.2021.716548"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.716548","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"article-number":"716548"}}